Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep:59 Suppl 1:S53-S60.
doi: 10.1002/ppul.26958. Epub 2024 Mar 19.

Pancreatitis in cystic fibrosis: Presentation, medical and surgical management, and the impact of modulator therapies

Reza V Milano  1 , Kayla Morneault-Gill  2 , Hebat Y Kamal  2 , Jodie A Barkin  1 , Christina Baldwin Chadwick  2
Affiliations
Review

Pancreatitis in cystic fibrosis: Presentation, medical and surgical management, and the impact of modulator therapies

Reza V Milano et al. Pediatr Pulmonol. 2024 Sep.

Abstract

Patients with Cystic Fibrosis (CF) are at increased risk of acute (AP) and chronic (CP) pancreatitis, and their complications. The extent of remaining healthy pancreatic parenchyma determines the risk of developing future episodes of pancreatitis, as well as pancreatic exocrine or endocrine insufficiency. Pancreatitis may be the presenting symptom of CF, and genetic testing is especially important in pediatrics. AP and recurrent AP are managed with intravenous fluid hydration and pain control, in addition to early refeeding and treatment of complications. With the use of modulator therapy in CF, pancreatic function may be restored to some extent. CP related pain is managed with analgesics and neuromodulators, with surgery if indicated in specific situations including TPIAT as a possible type of surgical intervention. Long-term sequelae of CP in patients with CF include exocrine pancreatic insufficiency treated with pancreatic enzyme replacement therapy, fat-soluble vitamin deficiencies and associated metabolic complications such as bone disease/osteoporosis, pancreatogenic diabetes, and less commonly, pancreatic cancer. We review the presentation and etiologies of pancreatitis in CF patients as well as the management of AP and CP primarily in children.

Keywords: acute pancreatitis; cystic fibrosis; management; modulator; pancreatitis.

PubMed Disclaimer

References

REFERENCES

    1. Polgreen PM, Comellas AP. Clinical phenotypes of cystic fibrosis carriers. Annu Rev Med. 2022;73:563‐574. doi:10.1146/annurev-med-042120-020148
    1. Wilschanski M, Durie PR. Pathology of pancreatic and intestinal disorders in cystic fibrosis. J R Soc Med. 1998;91 (suppl 34):40‐49. doi:10.1177/014107689809134S07
    1. Ooi CY, Durie PR. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cystic Fibros. 2012;11(5):355‐362. doi:10.1016/j.jcf.2012.05.001
    1. Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros. 2017;16(suppl 2):S70‐S78. doi:10.1016/j.jcf.2017.06.011
    1. De Boeck K, Vermeulen F, Dupont L. The diagnosis of cystic fibrosis. Presse medicale (Paris, France: 1983). 2017;46(6 Pt 2):e97‐e108doi:10.1016/j.lpm.2017.04.010

MeSH terms

Grants and funding